ASRT

Assertio Announces the Appointment of Brendan P. O’Grady as New CEO

Retrieved on: 
Mercoledì, Maggio 29, 2024
Patient, State university system, Business administration, Growth, Interim, Baker University, Glenmark Pharmaceuticals, ASRT, Master of Business Administration, Teva, Teva Pharmaceuticals, Management

Most recently, Mr. O’Grady was CEO of the Global Formulations business at Glenmark Pharmaceuticals, driving new product launches and focused on growing profitability in key markets.

Key Points: 
  • Most recently, Mr. O’Grady was CEO of the Global Formulations business at Glenmark Pharmaceuticals, driving new product launches and focused on growing profitability in key markets.
  • Prior, he was Chief Commercial and Growth Officer at Amwell, building a go-to-market strategy at the digital telehealth provider.
  • Peter Staple, Chairman of the Board, said, “The Board is delighted to welcome Brendan to Assertio as our new CEO.
  • We also look forward to Heather’s continuing contributions as she transitions back to her role as an independent director.”

Assertio to Participate in Benchmark Healthcare Conference on May 21-22

Retrieved on: 
Venerdì, Maggio 17, 2024
Patient, ASRT, Conference

LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.

Key Points: 
  • LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.
  • Investors participating in the Benchmark conference can request a meeting via their Benchmark representative, or contact Assertio investor relations via [email protected] .

Assertio to Participate in AGP Healthcare Conference on May 21

Retrieved on: 
Giovedì, Maggio 16, 2024
Patient, ASRT, AGP

Mr. Patel will present an overview of Assertio’s business at 3:40 p.m. Eastern Time.

Key Points: 
  • Mr. Patel will present an overview of Assertio’s business at 3:40 p.m. Eastern Time.
  • The event is hosted by AGP’s healthcare equity research team.
  • Investors interested in joining the conference can request to do so via their AGP representative, or contact Assertio investor relations via [email protected] .
  • Presentation information will be available on the day of the event and can accessed at https://investor.assertiotx.com.

Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024

Retrieved on: 
Giovedì, Aprile 25, 2024
ASRT, Software, ID, Patient, Telephone, Webcast

LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close.

Key Points: 
  • LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close.
  • Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
  • To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx .
  • A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.

Sig Kirk Joins Assertio Board of Directors

Retrieved on: 
Mercoledì, Aprile 3, 2024
AbbVie, Financial management, Certification, Barr Pharmaceuticals, Audit, Business administration, Patient, Pace University, ASRT, Compensation, Allergan, CPA

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.

Key Points: 
  • LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.
  • Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products.
  • Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification.
  • “Both Sig’s appointment and the addition of Sravan Emany last fall demonstrate our ongoing commitment to aligning our board expertise with our evolving business strategies.”

Assertio to Present at LD Micro Invitational Conference in New York City

Retrieved on: 
Lunedì, Aprile 1, 2024
Patient, Conference, ASRT, Software

LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.

Key Points: 
  • LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
  • The Company will host a group presentation at 4:00 pm Eastern Time, and be available for individual meetings throughout the day.
  • Attending investors interested in meeting with the Company can request a meeting on the conference platform, or contact Assertio investor relations via [email protected] .
  • Presentation information will be available on the day of the event and can accessed at https://investor.assertiotx.com .

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Giovedì, Marzo 28, 2024
Rheumatoid arthritis, Learning, EPS, Risk, Telephone, Patient, Suppository, Sale, Acquisition, News, ASRT, Complaint, Adjustment, P.C, Spectrum, Spectrum Pharmaceuticals, FDA, Food, Cryptocurrency

Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

GE HealthCare Announces the FDA Clearance of nCommand Lite by IONIC Health

Retrieved on: 
Lunedì, Marzo 25, 2024
Mobile, Wireless, Technology, Medical Devices, FDA, Health Technology, Software, Hardware, Radiology, Health, Data Management, PET/CT, Lite, Patient, ASRT, Workflow, GE HealthCare, Society, Digital Solutions, Radiographer, Medical imaging

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.
  • IONIC Health’s nCommand Lite includes multi-modality capabilities in support of magnetic resonance (MR), computed tomography (CT), and positron emission tomography/CT (PET/CT) scanning.
  • To further enhance its remote operations portfolio, GE HealthCare launched an FDA-cleared new version of Digital Expert Access and announced an exclusive distribution agreement with IONIC Health in November 2023.
  • “We are thrilled that our nCommand Lite solution, built on the three-year-strong nCommand platform from Brazil, is now cleared for use in the U.S.,” said José Leovigildo Coelho, CEO and co-founder of IONIC Health.

March 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ASRT

Retrieved on: 
Martedì, Marzo 5, 2024
Acquisition, Court, NEXT, Telephone, COST, Sale, Risk, CLASS, Spectrum Pharmaceuticals, LLP, ASRT, Cryptocurrency

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    ASRT investors may also contact Joseph E. Levi, Esq.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Lunedì, Marzo 4, 2024
Acquisition, FDA, News, Food, Zydus Lifesciences, Suppository, ASRT

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Assertio stock. Assertio investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ​ The Portnoy Law Firm advises Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Assertio stock.
  • Assertio investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.